COVID-19 has specifically impacted individuals with ADHD across different age groups, shedding light on the exacerbated difficulties in managing ADHD symptoms, executive functioning, and the additional struggle with depression and anxiety. By examining case studies, this piece will delineate how COVID-19 and ADHD have intersected in terms of their effects on daily living, work, and academic performance.
Is there a “cure” for ADHD on the horizon? There is no known “cure” for Attention Deficit Hyperactivity Disorder (ADHD) on the immediate horizon. ADHD is a complex neurodevelopmental disorder, and current research focuses more on managing symptoms rather than finding a cure.
Research indicates that people with Attention-Deficit/Hyperactivity Disorder (ADHD) are more likely than the general population to experience various forms of abuse, including physical, emotional, and sexual abuse.
Attention-Deficit/Hyperactivity Disorder (ADHD) and Bipolar Disorder are two distinct mental health conditions that can share some overlapping symptoms, making differential diagnosis challenging.Learn about the differences and similarities.
Individuals with ADHD may face higher medical expenses over a year or lifetime compared to those without the condition. Below are the details of the medical costs associated with ADHD:Individuals with Attention Deficit Hyperactivity Disorder (ADHD) can experience higher medical costs compared to those without the condition, both in a one-year period and over a lifetime. Here are some details on the medical costs associated with ADHD:
This is meant to health care professionals.
While the exact causes of ADHD are not fully understood, recent research has shed light on the potential involvement of brain insulin signaling in the disorder’s pathophysiology.
The remission of ADHD – What parents report?
How often does ADHD remit in children? At what age are parents most likely to report ADHD remission in their child, and what factors are associated with a greater likelihood of parent-reported remission?
There are several potential reasons why symptoms of attention deficit hyperactivity disorder (ADHD) may appear to increase or become more pronounced during or after perimenopause in some women.
It is plausible that exposure to cannabis in-utero could be associated with an increased risk of neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) symptoms and autism spectrum disorder (ASD) during childhood and adolescence; however, mixed results have been reported. This study investigated whether there is an association between prenatal cannabis use and ADHD symptoms and ASD in offspring using a systematic review and meta-analysis methodology.